San Francisco, 10 October 2018 - According to a report published by Grand View Research, Inc.; the global cancer stem cells market is anticipated to reach a revenue of around USD 1.6 billion by 2025. Increasing R&D initiatives for developing effective treatments based on stem cells can propel market growth. Rising awareness can further boost demand during the forecast period (2014 to 2025).
Significant rise in the number of published studies and ongoing research projects on Cancer Stem Cells (CSCs) are likely to create more growth opportunities for the market. These studies can help healthcare professionals to improve insights into CSCs biology and their signaling pathways. This factor is anticipated to bode well for the overall expansion of the market during the forecast period.
 |
Global Cancer Stem Cells Market Share, by Cancer Forms, 2016(%) |
Additionally, continuous progressions in experimental approaches such as in-vitro assay system have helped scientist establish the relationship between different tumors and their microenvironment. This has encouraged development of a wide range of therapeutics portfolio for CSCs and key pathways associated to restricting tumor development and providing satisfactory clinical results. This factor is anticipated to play a crucial role in overall expansion of the global market.
Browse In-depth Insights Cancer Stem Cells Market: www.grandviewresearch.com/industry-analysis/cancer-stem-cells-market
However, strict regulations regarding approval and usage of stem cell therapies are likely to hinder the market growth. Additionally, manufacturing and pharmacological issues related to development of cancer cell therapy is projected to slow down market growth during the forecast period.
The worldwide cancer stem cells market is segmented on the basis of mode of action, cancer forms, and region. As per mode of action, the market is categorized into targeted cancerous stem cells and stem cell-based cancer therapy. The targeted CSCs segment can be further segmented into anti-CSC therapeutics and pathway inhibitors, surface marker-based, immuno-evasion and targeting tumor microenvironment, nanoparticle-based therapies, and others. Anti-CSC therapeutics is anticipated to hold a significant market share over the forecast period due to rise in R&D activities.
Stem cell-based cancer therapy can be further bifurcated into autologous and allogeneic stem cell transplant. In 2016, the autologous stem cell transplant segment held the largest market share in terms of revenue due to high adoption. Factors such as affordability and better survival rate are other significant driving factors. The allogeneic segment is expected to showcase notable CAGR during the forecast period due to increasing focus on development of allogeneic cellular therapies.
Based on cancer forms, the market can be split into breast, liver, blood, brain, lung, colorectal, bladder, pancreatic, and other type of cancer. In 2016, breast segment accounted for the largest market share due to high prevalence and availability of a large number of therapeutics. Bladder cancer segment is expected to display the highest CAGR of 10.47% over the forecast period due to high prevalence.
The lung cancer segment is likely to register expansion at substantial CAGR over the projected period. This growth can be attributed to increasing development activities due to prevalence of lung malignance globally. In 2016, a team of researchers at the Department of Cancer Biology, Mayo Clinic established a combination therapy using a rheumatoid arthritis drug called auranofin to restrict the growth of lung CSCs.
Geographically, the market can be divided into North America, Asia Pacific, Europe, Latin America, and Middle East and Africa. In 2016, North America led the market in terms of revenue owing to presence of large number of organizations involved in R&D activities. Presence of a large number of well-established hospitals offering stem cell transplant in the U.S. can bode well for regional market growth.
Asia Pacific is expected to be the fastest growing region over the forecast period due to existence of numerous cancer and stem cell research organizations. In addition, increasing government funding and grants for research communities to accelerate cancer research can further boost regional expansion.
Key companies operating in the cancer stem cells market include OncoMed Pharmaceuticals, Inc.; Stemline Therapeutics, Inc.; MacroGenics, Inc.; PromoCell GmbH; and Miltenyi Biotec. Companies are adopting innovative strategies like facility expansion, new product launches, and strategic alliances to take advantage of growing popularity of stem cell therapy in clinical oncology.
Browse More Reports Of The Same Industry: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the global cancer stem cells market on the basis of mode of action, cancer forms, and region:
Cancer Stem Cells Mode of Action Outlook (Revenue, USD Million, 2014 - 2025)
- Targeted Cancerous Stem Cells (CSCs)
- By Anti-Cancer Stem Cell Therapeutics
- Pathway Inhibitors
- WNT Signaling Pathway
- Hedgehog Signaling Pathway
- Notch Signaling Pathway
- Others
- Surface Marker-based
- Immuno-evasion & Targeting Tumor Microenvironment
- Nanoparticle-based Therapies
- Others
- Pathway Inhibitors
- By Products
- Cell Culturing
- Cell Separation
- Cell Analysis
- Molecular Analysis
- Others
- Stem Cell-based Cancer Therapy
- Autologous Stem Cell Transplant
- Allogeneic Stem Cell Transplant
- By Anti-Cancer Stem Cell Therapeutics
Cancer Stem Cells Cancer Forms Outlook (Revenue, USD Million, 2014 - 2025)
- Breast Cancer
- Blood Cancer
- Lung Cancer
- Brain Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Bladder Cancer
- Liver Cancer
- Other Cancer
Cancer Stem Cells Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- US.
- Canada
- Europe
- Germany
- UK.
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Middle East & Africa
- South Africa
Browse Press Release of this Report: www.grandviewresearch.com/press-release/global-cancer-stem-cells-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment